Xizhi Wen

1.1k total citations
37 papers, 665 citations indexed

About

Xizhi Wen is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Xizhi Wen has authored 37 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 16 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Xizhi Wen's work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (11 papers). Xizhi Wen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (11 papers). Xizhi Wen collaborates with scholars based in China, United States and Hong Kong. Xizhi Wen's co-authors include Xiaoshi Zhang, Dandan Li, Xing Zhang, Jingjing Li, Jingjing Zhao, Ya Ding, Ruiqing Peng, Desheng Weng, Hongdi Ma and Wei Xiao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Immunity.

In The Last Decade

Xizhi Wen

36 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xizhi Wen China 15 415 287 239 102 66 37 665
Seiji Nagano Japan 12 335 0.8× 277 1.0× 232 1.0× 55 0.5× 26 0.4× 25 607
Robert Sanchez Rodriguez United States 6 416 1.0× 104 0.4× 379 1.6× 58 0.6× 32 0.5× 10 607
Christina Jensen Denmark 17 294 0.7× 165 0.6× 186 0.8× 77 0.8× 116 1.8× 35 612
María Ochoa de Olza Spain 14 521 1.3× 159 0.6× 275 1.2× 152 1.5× 82 1.2× 30 724
Claudine Graf Germany 15 209 0.5× 166 0.6× 224 0.9× 88 0.9× 52 0.8× 26 545
Konstantina Frangia Greece 10 388 0.9× 223 0.8× 353 1.5× 67 0.7× 34 0.5× 25 767
John Galbincea United States 10 361 0.9× 293 1.0× 66 0.3× 106 1.0× 94 1.4× 13 636
Keyon Taravati United States 8 406 1.0× 117 0.4× 451 1.9× 61 0.6× 35 0.5× 8 671
Loreto Spencer Chile 13 239 0.6× 191 0.7× 121 0.5× 138 1.4× 59 0.9× 34 604
Jan Davidson‐Moncada United States 12 228 0.5× 161 0.6× 215 0.9× 61 0.6× 117 1.8× 49 518

Countries citing papers authored by Xizhi Wen

Since Specialization
Citations

This map shows the geographic impact of Xizhi Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xizhi Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xizhi Wen more than expected).

Fields of papers citing papers by Xizhi Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xizhi Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xizhi Wen. The network helps show where Xizhi Wen may publish in the future.

Co-authorship network of co-authors of Xizhi Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Xizhi Wen. A scholar is included among the top collaborators of Xizhi Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xizhi Wen. Xizhi Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Jiayong, Tian Gao, Qiuzhong Pan, et al.. (2024). Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.. Journal of Clinical Oncology. 42(16_suppl). 11548–11548. 1 indexed citations
3.
Li, Dandan, et al.. (2024). Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence. Journal of Neuro-Oncology. 170(3). 665–673. 2 indexed citations
4.
Li, Dandan, Chao Chen, Jingjing Li, et al.. (2023). A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors. Nature Communications. 14(1). 3447–3447. 6 indexed citations
5.
Si, Lu, Xiaoshi Zhang, Yongqian Shu, et al.. (2022). Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Frontiers in Immunology. 13. 882471–882471. 18 indexed citations
6.
Wen, Xizhi, Jingjing Li, Hang Jiang, et al.. (2022). HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. Frontiers in Immunology. 13. 902167–902167. 13 indexed citations
7.
Wen, Xizhi, Qiuzhong Pan, Wei Xiao, et al.. (2022). Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemotherapy and Pharmacology. 89(2). 209–215. 15 indexed citations
8.
9.
Zhao, Jingjing, Dandan Li, Xinpei Deng, et al.. (2022). Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population–based analysis. Frontiers in Immunology. 13. 1083840–1083840. 22 indexed citations
10.
Li, Jingjing, Xizhi Wen, Wei Liu, et al.. (2022). Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Scientific Reports. 12(1). 9559–9559. 14 indexed citations
11.
Que, Yi, Xiao-Long Zhang, Xiao-Long Zhang, et al.. (2021). Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. Journal for ImmunoTherapy of Cancer. 9(2). e001696–e001696. 67 indexed citations
12.
Li, Jingjing, Dandan Li, Xizhi Wen, et al.. (2021). Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology. 148(5). 1159–1169. 17 indexed citations
13.
Wen, Xizhi, Leyi Yao, Zhenlong Shao, et al.. (2021). Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling. Frontiers in Oncology. 11. 698888–698888. 3 indexed citations
14.
Wen, Xizhi, Dandan Li, Jingjing Zhao, et al.. (2020). Time-varying pattern of recurrence risk for localized melanoma in China. World Journal of Surgical Oncology. 18(1). 6–6. 7 indexed citations
15.
Xiao, Wei, Jinghua Wang, Xizhi Wen, et al.. (2020). Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma. Cancer. 126(S9). 2093–2100. 16 indexed citations
16.
Si, Lu, Xiaoshi Zhang, Yongqian Shu, et al.. (2019). A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology. 12(6). 828–835. 99 indexed citations
17.
Xiao, Wei, Yi Que, Ruiqing Peng, et al.. (2018). A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure. OncoTargets and Therapy. Volume 11. 2439–2443. 9 indexed citations
18.
Pan, Wen, Shu Zhu, Kun Qu, et al.. (2017). The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression. Immunity. 47(2). 284–297.e5. 138 indexed citations
19.
Wen, Xizhi, Yao Wang, Ya Ding, et al.. (2016). Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research. 26(3). 284–289. 21 indexed citations
20.
Niu, Haitao, Fang Wang, Qiong Shao, et al.. (2013). Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell & Melanoma Research. 26(5). 646–653. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seiji Nagano Breakdown of academic impact, for papers by Robert Sanchez Rodriguez Breakdown of academic impact, for papers by Christina Jensen Breakdown of academic impact, for papers by María Ochoa de Olza Breakdown of academic impact, for papers by Claudine Graf Breakdown of academic impact, for papers by Konstantina Frangia Breakdown of academic impact, for papers by John Galbincea Breakdown of academic impact, for papers by Keyon Taravati Breakdown of academic impact, for papers by Loreto Spencer Breakdown of academic impact, for papers by Jan Davidson‐Moncada
Rankless by CCL
2026